vs
Side-by-side financial comparison of Richmond Mutual Bancorporation, Inc. (RMBI) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $13.1M, roughly 1.6× Richmond Mutual Bancorporation, Inc.). Richmond Mutual Bancorporation, Inc. runs the higher net margin — 26.1% vs -20.4%, a 46.5% gap on every dollar of revenue. On growth, Richmond Mutual Bancorporation, Inc. posted the faster year-over-year revenue change (18.1% vs 6.9%). Richmond Mutual Bancorporation, Inc. produced more free cash flow last quarter ($14.6M vs $-2.0M). Over the past eight quarters, Richmond Mutual Bancorporation, Inc.'s revenue compounded faster (9.1% CAGR vs 2.9%).
Richmond Mutual Bancorporation, Inc. is a U.S.-based bank holding company operating primarily in Indiana. It offers a full range of personal and commercial banking solutions including deposit accounts, mortgage loans, small business lending, and wealth management services, serving local retail consumers and small-to-medium enterprise clients via its regional branch network.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
RMBI vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.1M | $20.4M |
| Net Profit | $3.4M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | — | -18.0% |
| Net Margin | 26.1% | -20.4% |
| Revenue YoY | 18.1% | 6.9% |
| Net Profit YoY | 37.7% | 64.9% |
| EPS (diluted) | $0.35 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.1M | $20.4M | ||
| Q3 25 | $12.6M | $19.9M | ||
| Q2 25 | $11.8M | $19.6M | ||
| Q1 25 | $11.4M | $17.5M | ||
| Q4 24 | $11.1M | $19.1M | ||
| Q3 24 | $10.8M | $20.2M | ||
| Q2 24 | $10.7M | $21.4M | ||
| Q1 24 | $11.0M | $19.3M |
| Q4 25 | $3.4M | $-4.2M | ||
| Q3 25 | $3.6M | $-8.2M | ||
| Q2 25 | $2.6M | $-11.9M | ||
| Q1 25 | $2.0M | $-14.2M | ||
| Q4 24 | $2.5M | $-11.8M | ||
| Q3 24 | $2.5M | $-11.1M | ||
| Q2 24 | $2.1M | $-12.3M | ||
| Q1 24 | $2.4M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | — | -18.0% | ||
| Q3 25 | — | -39.7% | ||
| Q2 25 | — | -59.6% | ||
| Q1 25 | — | -79.2% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | — | -55.7% | ||
| Q2 24 | — | -59.2% | ||
| Q1 24 | — | -76.4% |
| Q4 25 | 26.1% | -20.4% | ||
| Q3 25 | 28.6% | -41.0% | ||
| Q2 25 | 22.0% | -61.0% | ||
| Q1 25 | 17.2% | -80.8% | ||
| Q4 24 | 22.4% | -62.1% | ||
| Q3 24 | 23.0% | -54.9% | ||
| Q2 24 | 19.3% | -57.7% | ||
| Q1 24 | 21.6% | -84.4% |
| Q4 25 | $0.35 | $-0.07 | ||
| Q3 25 | $0.36 | $-0.16 | ||
| Q2 25 | $0.26 | $-0.23 | ||
| Q1 25 | $0.20 | $-0.28 | ||
| Q4 24 | $0.25 | $-0.23 | ||
| Q3 24 | $0.24 | $-0.22 | ||
| Q2 24 | $0.20 | $-0.25 | ||
| Q1 24 | $0.23 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.1M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $145.8M | $63.9M |
| Total Assets | $1.5B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.1M | $92.0M | ||
| Q3 25 | $34.3M | $92.4M | ||
| Q2 25 | $27.2M | $101.5M | ||
| Q1 25 | $27.0M | $108.8M | ||
| Q4 24 | $21.8M | $120.4M | ||
| Q3 24 | $19.6M | $118.6M | ||
| Q2 24 | $19.0M | $118.2M | ||
| Q1 24 | $20.3M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $145.8M | $63.9M | ||
| Q3 25 | $140.0M | $64.3M | ||
| Q2 25 | $132.3M | $70.0M | ||
| Q1 25 | $130.9M | $77.6M | ||
| Q4 24 | $132.9M | $87.5M | ||
| Q3 24 | $140.0M | $95.0M | ||
| Q2 24 | $131.1M | $101.6M | ||
| Q1 24 | $132.4M | $109.2M |
| Q4 25 | $1.5B | $115.3M | ||
| Q3 25 | $1.5B | $116.3M | ||
| Q2 25 | $1.5B | $122.0M | ||
| Q1 25 | $1.5B | $129.7M | ||
| Q4 24 | $1.5B | $142.8M | ||
| Q3 24 | $1.5B | $143.6M | ||
| Q2 24 | $1.5B | $149.7M | ||
| Q1 24 | $1.5B | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.0M | $-1.8M |
| Free Cash FlowOCF − Capex | $14.6M | $-2.0M |
| FCF MarginFCF / Revenue | 111.9% | -9.7% |
| Capex IntensityCapex / Revenue | 10.4% | 0.8% |
| Cash ConversionOCF / Net Profit | 4.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | $26.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.0M | $-1.8M | ||
| Q3 25 | $6.3M | $-8.7M | ||
| Q2 25 | $4.8M | $-7.5M | ||
| Q1 25 | $2.2M | $-11.6M | ||
| Q4 24 | $14.8M | $-3.5M | ||
| Q3 24 | $2.9M | $362.0K | ||
| Q2 24 | $2.9M | $-9.5M | ||
| Q1 24 | $2.2M | $-9.8M |
| Q4 25 | $14.6M | $-2.0M | ||
| Q3 25 | $5.8M | $-8.9M | ||
| Q2 25 | $4.2M | $-7.8M | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $14.3M | $-3.6M | ||
| Q3 24 | $2.8M | $311.0K | ||
| Q2 24 | $2.8M | $-9.5M | ||
| Q1 24 | $2.0M | $-9.9M |
| Q4 25 | 111.9% | -9.7% | ||
| Q3 25 | 46.2% | -44.7% | ||
| Q2 25 | 35.6% | -39.6% | ||
| Q1 25 | 18.4% | — | ||
| Q4 24 | 129.3% | -18.9% | ||
| Q3 24 | 25.7% | 1.5% | ||
| Q2 24 | 26.2% | -44.7% | ||
| Q1 24 | 18.7% | -51.4% |
| Q4 25 | 10.4% | 0.8% | ||
| Q3 25 | 3.7% | 0.9% | ||
| Q2 25 | 5.3% | 1.1% | ||
| Q1 25 | 0.7% | 0.0% | ||
| Q4 24 | 4.2% | 0.7% | ||
| Q3 24 | 1.1% | 0.3% | ||
| Q2 24 | 1.1% | 0.4% | ||
| Q1 24 | 1.1% | 0.6% |
| Q4 25 | 4.68× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.86× | — | ||
| Q1 25 | 1.11× | — | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | 1.17× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RMBI
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
